Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Sch 1 Update - ISIS Resources

15 Sep 2006 11:23

AIM15 September 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: Verona Pharma plc (previously Isis Resources plc) COMPANY ADDRESS: Adderbury Hill Barn, Milton Road, Adderbury, Oxon COMPANY POSTCODE: OX17 3HN COUNTRY OF INCORPORATION: United Kingdom COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: The company is involved in drug discovery focused on the discovery and development of new therapeutic drugs for thetreatment of allergic rhinitis (hay fever) and other chronic respiratory and inflammatory diseases. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 144,275,000 Ordinary Shares of £0.001 each CAPITAL TO BE RAISED ON ADMISSION: £2.043 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Professor Clive Peter Page, Non-Executive Chairman Professor Michael John Alfred Walker, Chief Executive Officer Claire Louise Poll, Executive Director Professor Trevor Mervyn Jones, Non-Executive Director Herbert Stuart Bottomley, Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Prior to Admission %Craig Burton* 19.9Pershing Keen Nominees Ltd** 18.5Williams de Broe 7.0Stuart Bottomley*** 7.0Josef El Raghy 6.0Fitel Nominees Ltd a/c CO57658 5.6Jamie Boyton 4.8William Fairweather 4.6Fitel Nominees Ltd a/c CO58142 4.2Mark Freeman 4.0Tolle Investments Pty Ltd 4.0 * Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A/C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited After admission %Fidelity Euro Smaller Companies Fund 9.70Craig Burton* 8.66Pershing Keen Nominees Ltd** 6.42Williams de Broe 5.80Stuart Bottomley*** 4.16Clive Page 3.92Michael Walker 3.91David Saint 3.91Millenium Capital Partners 3.19* Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A /C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: None ANTICIPATED ACCOUNTING REFERENCE DATE: 31 December EXPECTED ADMISSION DATE: 19 September 2006 NAME AND ADDRESS OF NOMINATED ADVISER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ NAME AND ADDRESS OF BROKER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DATE OF NOTIFICATION:15 September 2006UPDATE Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Sep 20167:00 amPRNHalf-year Report
12th Sep 20167:00 amPRNAppointment of Vikas Sinha as Non-Executive Director
30th Aug 20167:00 amPRNData on RPL554 to be presented at ERS Congress
10th Aug 20169:59 amPRNNotice of Results
9th Aug 20162:16 pmRNSDirector Dealing
5th Aug 20169:27 amRNSHolding(s) in Company
4th Aug 20163:26 pmPRNGrant of Share Options
4th Aug 20168:45 amRNSHolding(s) in Company
3rd Aug 20169:03 amRNSHolding(s) in Company
3rd Aug 20168:43 amRNSHolding(s) in Company
3rd Aug 20168:37 amRNSHolding(s) in Company
2nd Aug 20164:26 pmRNSHolding(s) in Company - Replacement
2nd Aug 201611:26 amRNSHolding(s) in Company
1st Aug 20163:57 pmRNSHolding(s) in Company
1st Aug 201611:40 amRNSHolding(s) in Company
1st Aug 201611:20 amRNSHolding(s) in Company
29th Jul 20168:06 amPRNAdmission of Placing Shares
22nd Jul 201611:32 amPRNResult of GM
1st Jul 20168:00 amPRNNotice of GM
27th Jun 20161:42 pmPRNResult of AGM
20th Jun 20167:00 amPRNProposed Placing and Notice of General Meeting
17th Jun 20164:54 pmPRNProposed Placing and Notice of General Meeting
3rd Jun 20165:26 pmPRN2015 Annual Report and Accounts, Notice of AGM
3rd Jun 20167:00 amPRNFinal Results
27th May 20162:48 pmPRNNotice of Results
10th May 20167:00 amPRNAdd-on Phase II RPL554 study
4th May 20167:00 amPRNVerona to present RPL554 at the ATS Conference
19th Apr 20163:16 pmPRNChange of Registered Office
15th Apr 20164:08 pmRNSHolding(s) in Company
21st Mar 20167:00 amPRNVerona Pharma: 2015 in review
15th Mar 20167:00 amPRNPositive results from RPL554 dose-finding study
10th Feb 20162:47 pmPRNGrant of Share Options
21st Jan 201612:24 pmRNSDirector Dealing
11th Jan 20167:00 amPRNDirectorate Change
3rd Dec 20154:02 pmPRNDirector Dealing
1st Dec 20155:11 pmRNSHolding(s) in Company
11th Nov 20157:00 amPRNRPL554 paper published in American Journal of Physiology
5th Nov 20157:00 amPRNPatient enrolment completed in RPL554 PhIIa studies
14th Oct 20157:00 amPRNStart of RPL554 Phase IIa combination study
8th Oct 201511:30 amPRNRPL554 data presented at North American CF Conference
29th Sep 20157:00 amPRNPositive headline data from RPL554 study
8th Sep 20157:00 amPRNBoard Changes
8th Sep 20157:00 amPRNHalf-yearly Report
27th Aug 20157:00 amPRNNotice of Results
7th Jul 20154:45 pmPRNDirector Dealing
17th Jun 20155:02 pmPRNDirector Dealings
12th Jun 20157:00 amPRNSecondary listing in Germany
11th Jun 20151:00 pmPRNResult of AGM
11th Jun 20157:00 amPRNRPL554 Phase 2a trial started
8th Jun 20157:00 amPRNRPL554 MAD study complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.